FDA approves nivolumab plus cisplatin/gemcitabine in urothelial carcinoma
March 7th 2024The approval is based on data from the phase 3 CheckMate-901 trial, which demonstrated improved overall survival and progression-free survival with the nivolumab-combination therapy vs cisplatin/gemcitabine alone.
Long-term data highlight efficacy of adjuvant chemotherapy in UTUC
February 28th 2024Adjuvant chemotherapy after nephroureterectomy continued to show an efficacy benefit versus surveillance in patients with upper tract urothelial cancer, according to long-term follow-up data from the phase 3 randomized POUT trial.
Prostate cancer report card aims to improve patients’ understanding of treatment options
February 6th 2024“The more informed the patients are, the more likely they are to participate in decision making…Patient engagement in decisions reduces decisional regret and fosters patient satisfaction with treatment outcomes,” the researchers wrote.
FDA approves enfortumab vedotin plus pembrolizumab for urothelial carcinoma
December 15th 2023The approval is supported by findings from the phase 3 EV-302 trial, which showed that the combination led to significant improvements in overall survival and progression-free survival compared with chemotherapy.